Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELZ Creative Medical Technology	$3.19 +0.9%	$2.83	$1.69 ▼ $6.90	$8.15M	2.04	170,314 shs	43,486 shs
KZR Kezar Life Sciences	$4.06 +2.8%	$4.28	$3.62 ▼ $9.18	$28.93M	0.65	40,538 shs	24,873 shs
MRSN Mersana Therapeutics	$7.75 -4.4%	$7.84	$5.21 ▼ $70.75	$40.47M	0.83	130,808 shs	71,731 shs
TPST Tempest Therapeutics	$10.02 +7.2%	$7.51	$5.33 ▼ $20.67	$41.52M	-1.93	108,739 shs	42,739 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELZ Creative Medical Technology	+0.95%	+2.24%	+15.16%	+57.92%	-3.92%
KZR Kezar Life Sciences	+2.78%	+2.27%	-5.58%	+3.31%	-35.70%
MRSN Mersana Therapeutics	-4.44%	+8.24%	-23.57%	-12.01%	-77.70%
TPST Tempest Therapeutics	+7.17%	-4.84%	+60.32%	+60.83%	-47.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CELZ Creative Medical Technology	1.5327 of 5 stars	0.0	5.0	0.0	3.9	0.0	0.6
KZR Kezar Life Sciences	3.8639 of 5 stars	3.2	0.0	4.6	2.0	3.3	0.6
MRSN Mersana Therapeutics	4.2332 of 5 stars	3.5	4.0	4.1	1.8	2.5	0.0
TPST Tempest Therapeutics	1.208 of 5 stars	3.3	2.0	0.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELZ Creative Medical Technology	2.00	Hold	N/A	N/A
KZR Kezar Life Sciences	2.33	Hold	$9.00	121.67% Upside
MRSN Mersana Therapeutics	3.00	Buy	$56.60	630.32% Upside
TPST Tempest Therapeutics	2.50	Moderate Buy	$30.00	199.40% Upside

Current Analyst Ratings Breakdown

Latest CELZ, MRSN, TPST, and KZR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$250.00 ➝ $36.00
8/14/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$125.00 ➝ $30.00
8/13/2025	MRSN Mersana Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
8/12/2025	CELZ Creative Medical Technology	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/16/2025	KZR Kezar Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELZ Creative Medical Technology	$10K	823.02	N/A	N/A	$2.65 per share	1.20
KZR Kezar Life Sciences	$7M	4.25	N/A	N/A	$12.53 per share	0.32
MRSN Mersana Therapeutics	$40.50M	0.95	N/A	N/A	($10.65) per share	-0.73
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$2.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELZ Creative Medical Technology	-$5.49M	-$3.18	N/A	N/A	N/A	N/A	-82.99%	-79.49%	N/A
KZR Kezar Life Sciences	-$83.74M	-$9.69	N/A	N/A	N/A	N/A	-63.51%	-52.13%	11/11/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$14.62	N/A	N/A	N/A	-212.94%	-990.16%	-54.85%	N/A
TPST Tempest Therapeutics	-$41.84M	-$14.59	N/A	N/A	N/A	N/A	-334.76%	-130.63%	11/11/2025 (Estimated)

Latest CELZ, MRSN, TPST, and KZR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	KZR Kezar Life Sciences	-$2.15	-$1.87	+$0.28	-$1.87	N/A	N/A
8/13/2025	Q2 2025	MRSN Mersana Therapeutics	-$3.75	-$4.08	-$0.33	-$4.87	$6.06 million	$3.06 million
8/11/2025	Q2 2025	TPST Tempest Therapeutics	-$3.23	-$2.07	+$1.16	-$2.07	N/A	N/A
8/8/2025	Q2 2025	CELZ Creative Medical Technology	-$0.63	-$0.48	+$0.15	-$0.48	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELZ Creative Medical Technology	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELZ Creative Medical Technology	N/A	23.86	23.86
KZR Kezar Life Sciences	0.03	7.29	7.29
MRSN Mersana Therapeutics	N/A	1.35	1.35
TPST Tempest Therapeutics	N/A	2.12	2.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELZ Creative Medical Technology	1.42%
KZR Kezar Life Sciences	67.90%
MRSN Mersana Therapeutics	93.92%
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
CELZ Creative Medical Technology	2.80%
KZR Kezar Life Sciences	10.40%
MRSN Mersana Therapeutics	13.00%
TPST Tempest Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELZ Creative Medical Technology	5	2.58 million	2.51 million	Not Optionable
KZR Kezar Life Sciences	60	7.32 million	6.56 million	Not Optionable
MRSN Mersana Therapeutics	150	4.99 million	4.34 million	Optionable
TPST Tempest Therapeutics	20	4.44 million	4.23 million	Optionable

CELZ, MRSN, TPST, and KZR Headlines

Recent News About These Companies

Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025 | finanznachrichten.de

Tempest Therapeutics Advances Clinical Development with Orphan Drug Designations and Pivotal Trial Clearance for Amezalpat and TPST-1495

August 11, 2025 | quiverquant.comQ

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

August 11, 2025 | globenewswire.com

Morpheus-Liver Study: A New Horizon in Advanced Liver Cancer Treatment

August 4, 2025 | tipranks.com

Tempest Therapeutics’ Promising Advances in Liver Cancer Treatment

July 3, 2025 | tipranks.com

Tempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China - Nasdaq

July 2, 2025 | nasdaq.com

Tempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China

June 30, 2025 | quiverquant.comQ

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

June 30, 2025 | globenewswire.com

TPST - Tempest Therapeutics Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

TPST Tempest Therapeutics, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13%

June 11, 2025 | msn.com

Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock

June 11, 2025 | quiverquant.comQ

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

June 11, 2025 | globenewswire.com

Tempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic Alternatives

June 7, 2025 | marketwatch.com

Tempest Therapeutics Shares Up, Executive Team Enters Into Consulting Agreements

June 7, 2025 | marketwatch.com

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

June 6, 2025 | zacks.com

Tempest Therapeutics stock rises on EMA Orphan Drug Designation

June 5, 2025 | au.investing.com

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

June 5, 2025 | globenewswire.com

Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ, MRSN, TPST, and KZR Company Descriptions

Creative Medical Technology NASDAQ:CELZ

$3.19 +0.03 (+0.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.15 -0.04 (-1.25%)

As of 08/22/2025 07:42 PM Eastern

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Kezar Life Sciences NASDAQ:KZR

$4.06 +0.11 (+2.78%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$4.07 +0.01 (+0.12%)

As of 08/22/2025 07:32 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Mersana Therapeutics NASDAQ:MRSN

$7.75 -0.36 (-4.44%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.76 +0.01 (+0.19%)

As of 08/22/2025 07:51 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Tempest Therapeutics NASDAQ:TPST

$10.02 +0.67 (+7.17%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$10.02 0.00 (0.00%)

As of 08/22/2025 07:46 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time